Table 2.
Overview of clinical imaging studies with 68Ga-Sstr-analogues in PNETs
| Radiopharmaceutical | Authors (Ref.) | Design | No of pts. | Quantitative parameters (SUVmax) | Diagnostic performance (Sens./Specif.) | “Gold”/Reference standard |
|---|---|---|---|---|---|---|
| 68Ga-DOTA-TOC | Gabriel et al. (20) | Prospective | 84 | Not done | Sensitivity 100 %, Specificity 88.8 %* | Follow-up/Histopathology |
| Gabriel et al. (21) | Retrospective | 46 | Mean 43.6 (range 20.5–94) | N ot done | Follow-up | |
| Kroiss et al. (22) | Retrospective | 249 | Cut-off 17.1 (malignant/non-malignant) | Sensitivity 90 %, Specificity 93.6 % | Follow-up | |
| 311 studies | 6.5 ± 2.5 (range 1.6–20.7) pancreatic body | |||||
| 311 studies | 10.5 ± 4.1 (range 2.9–28.7) uncinate process | |||||
| 30 | Mean 33.6 ± 14.3 PNET uncinate process | |||||
| 13 | Mean 36.3 ± 21.5 PNET pancreatic tail | |||||
| Al-Ibraheem et al. (23) | Retrospective | 43 | Pancreatic to liver ratio range 3.24–9.1 | Not done | Follow-up | |
| 23 | 4.0 ± 0.8 (range 2.4–5.3) no visible uptake | |||||
| 20 | 9.3 ± 3.1 (range 5.1–15.5) no pathology | |||||
| 3/20 | 51.6 ± 15.7 (range 34.1–64.2) PNET | Histopathology | ||||
| Kumar et al. (24) | Retrospective | 20 | Median 12.6 (range 8.8–27.6) | Sensitivity 100 % | Follow-up/Histopathology | |
| Jacobsson et al. (26) | Retrospective | 50 | Mean 9.2 ± 2.9 (without pathology) | Not done | Concomitant CT | |
| 68Ga-DOTA-NOC | Prasad V, Baum RP (25) | Retrospective | 50 | Mean 5.8 ± 2.0 (range 4–9.7) non-malignant | Not done | Follow-up |
| 26 | Mean 20.8 ± 10.8 PNET | |||||
| Cut off 8.6 malignant/non-malignant | ||||||
| Castellucci et al. (27) | Retrospective | 100 | Mean 12.6 ± 2.2 non-malignant | Not done | Follow-up | |
| Prasad et al. (28) | Retrospective | 59 | Mean 18.6 ± 9.8 (range 7.8–34.8) previously unknown PNET | Not done | Follow-up | |
| Mean 26.1 ± 14.5 (range 8.7–42.4) previously known PNET | ||||||
| Krausz et al. (29) | Retrospective | 96 | (Range 4.7–165) suspected PNET | Not done | Follow-up | |
| 35 | Mean 25.7 ± 28.8 (range 5.5–165) PNET | |||||
| Sharma et al. (30) | Retrospective | 141 | Mean 14.7 ± 6 (range 5–32.5) | Sensitivity 85.7 %, Specificity 79.1 % | Follow-up/Histopathology | |
| 68Ga-DOTA-TATE | Wild et al. (33) | Retrospective | 8 | Median 3.5 (range 3.0–4.3) | Not done | Follow-up/Histopathology |
| Skoura et al. (34) | Retrospective | 728 | Not done | Sensitivity 97 %, Specificity 95.1 %§ | Follow-up | |
| Kunikowska et al. (36) | Retrospective | 250 | Mean 9.2 ± 3.3 without pathology in 41/250 pts (16.4 %) | Not done | Follow-up | |
| Haug et al. (37) | Retrospective | 104 | Not done | Sensitivity 81 % %, Specificity 90 %& | 8 of 36 histologically verified tumours were in the pancreas | |
| Schmid-Tannwald et al. (39) | Retrospective | 18 | Mean 36.46 ± 27.38 (range 6.2 to 120) | Not done | Histopathology | |
| Etchebehere et al. (40) | Prospective | 19 | Not done | Sensitivity 100 %, Specificity 80 % | Follow-up/Histopathology | |
| *with regard to patients with suspected NETs | ||||||
| §14 FP in 1258 scans, 4 of them for the pancreas | ||||||
| &7 FP and 7 FN, sites of findings not indicated |